136
Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
 a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations: Subject; CYP2C19 and CYP3A5 heterozygous mutations: Subject.Disorder; Hepatic drug interaction: Effect; tacrolimus and lansoprazole: Treatment; voriconazole: Treatment; bone marrow transplant: Treatment.Disorder; tacrolimus: Treatment.Drug; lansoprazole: Treatment.Drug; voriconazole: Treatment.Drug; tacrolimus: Combination.Drug; lansoprazole: Combination.Drug; voriconazole: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations: Subject; CYP2C19 and CYP3A5 heterozygous mutations: Subject.Disorder; Hepatic drug interaction: Effect; tacrolimus and lansoprazole: Treatment; voriconazole: Treatment; bone marrow transplant: Treatment.Disorder; tacrolimus: Treatment.Drug; lansoprazole: Treatment.Drug; voriconazole: Treatment.Drug; tacrolimus: Combination.Drug; lansoprazole: Combination.Drug; voriconazole: Combination.Drug